
Thermo Fisher Scientific Inc.
Thermo Fisher
Thermo Fisher Scientific Inc. is the world's largest provider of scientific instrumentation, reagents, and laboratory services, headquartered in Waltham, Massachusetts. Founded in 1956 as Thermo Electron and reorganized through the 2006 merger with Fisher Scientific, the company generates US$44.6 billion in annual revenue with approximately 125,000 employees across four business segments — Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services. Its end-to-end "sample to insight" portfolio, built through decades of strategic acquisitions, covers the entire biopharmaceutical research and manufacturing workflow, making it an infrastructural partner for the global life sciences and healthcare industries.
Strengths:
• Closed-loop manufacturing – full in-house production from reagents and cell culture media to mass spectrometers and gene sequencers, with facilities in more than 50 countries
• One-stop-shop ecosystem – high customer switching costs created by the industry's broadest portfolio spanning research, diagnostics, and biopharma services
• Category leadership – dominant positions in mass spectrometry, electron microscopy (FEI), and bioprocessing consumables
• Financial scale – US$44.6 billion revenue funds the industry's largest R&D budget and a formidable M&A engine
Weaknesses:
• R&D budget exposure – performance is highly correlated with global government and private R&D expenditure and capital investment cycles
• China trade headwinds – an anticipated US$400 million China revenue decline from trade tensions pressured 2025 guidance
• Regulatory burden – stringent worldwide medical device and diagnostics regulations raise compliance costs and time-to-marketRead More ▼Show Less ▲
Strengths:
• Closed-loop manufacturing – full in-house production from reagents and cell culture media to mass spectrometers and gene sequencers, with facilities in more than 50 countries
• One-stop-shop ecosystem – high customer switching costs created by the industry's broadest portfolio spanning research, diagnostics, and biopharma services
• Category leadership – dominant positions in mass spectrometry, electron microscopy (FEI), and bioprocessing consumables
• Financial scale – US$44.6 billion revenue funds the industry's largest R&D budget and a formidable M&A engine
Weaknesses:
• R&D budget exposure – performance is highly correlated with global government and private R&D expenditure and capital investment cycles
• China trade headwinds – an anticipated US$400 million China revenue decline from trade tensions pressured 2025 guidance
• Regulatory burden – stringent worldwide medical device and diagnostics regulations raise compliance costs and time-to-market
Business Nature
Core Business Areas
Industry Rankings
Corporate Report
VerityRank Score
Based on market presence, financial scale, operational capacity, and brand strength.
Quick Facts
Headquarters
Waltham, Massachusetts, USA
Founded
1956
Employees
130K+
Factories
100+ Production Base
Listing
NYSE: TMOCategories
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website NYSE:TMO , Thermo Fisher Q4 & FY 2025 Results
Thermo Fisher 2025 10-K (SEC)
Mordor Intelligence — API Market
